Abstract
In 2019, 2 novel pharmaceutical agents for small animals were released on the German market: The non-steroidal, non-cyclooxygenase inhibiting anti-inflammatory agent grapiprant (Galliprant®) of the piprant class as well as fluorescein (Ophtorescein®), a xanthen dye-based diagnostic agent for corneal defects. One substance was authorized for an additional species: The antidiabetic protamine zinc insulin of human origin (ProZinc®) is now additionally authorized for dogs. Additionally, one veterinary drug with a new combination of active ingredients (fluralaner + moxidectin), 5 agents in a novel pharmaceutical formulation (acepromazine, chloramphenicol, dexamethasone, metronidazole, torasemide), one drug (lidocaine) with a new route of administration, as well as one agent (apomorphine) in a new primary packaging with extended opening stability have been launched on the market for small animals.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Tierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
